Cytek Biosciences Stock Performance
| CTKB Stock | USD 4.50 0.43 8.72% |
The firm shows a Beta (market volatility) of 2.01, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytek Biosciences will likely underperform. Cytek Biosciences right now shows a risk of 4.3%. Please confirm Cytek Biosciences expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Cytek Biosciences will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cytek Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward-looking signals, Cytek Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 167.6 M | |
| Total Cashflows From Investing Activities | -83 M |
Cytek Biosciences Relative Risk vs. Return Landscape
If you would invest 462.00 in Cytek Biosciences on November 7, 2025 and sell it today you would lose (12.00) from holding Cytek Biosciences or give up 2.6% of portfolio value over 90 days. Cytek Biosciences is currently generating 0.0433% in daily expected returns and assumes 4.3029% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Cytek, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytek Biosciences Target Price Odds to finish over Current Price
The tendency of Cytek Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.50 | 90 days | 4.50 | about 98.0 |
Based on a normal probability distribution, the odds of Cytek Biosciences to move above the current price in 90 days from now is about 98.0 (This Cytek Biosciences probability density function shows the probability of Cytek Stock to fall within a particular range of prices over 90 days) .
Cytek Biosciences Price Density |
| Price |
Predictive Modules for Cytek Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cytek Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cytek Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cytek Biosciences is not an exception. The market had few large corrections towards the Cytek Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cytek Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cytek Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | 2.01 | |
σ | Overall volatility | 0.34 | |
Ir | Information ratio | -0.0004 |
Cytek Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cytek Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cytek Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cytek Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 105.23 M. | |
| About 64.0% of the company shares are held by institutions such as insurance companies |
Cytek Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cytek Stock often depends not only on the future outlook of the current and potential Cytek Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cytek Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 130.6 M | |
| Cash And Short Term Investments | 277.9 M |
Cytek Biosciences Fundamentals Growth
Cytek Stock prices reflect investors' perceptions of the future prospects and financial health of Cytek Biosciences, and Cytek Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytek Stock performance.
| Return On Equity | -0.0336 | ||||
| Return On Asset | -0.0436 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 424.15 M | ||||
| Shares Outstanding | 127.86 M | ||||
| Price To Book | 1.71 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 200.45 M | ||||
| EBITDA | (10.03 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 17.02 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 2.96 X | ||||
| Cash Flow From Operations | 25.38 M | ||||
| Earnings Per Share | (0.11) X | ||||
| Total Asset | 499.5 M | ||||
| Retained Earnings | (35.2 M) | ||||
About Cytek Biosciences Performance
By analyzing Cytek Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cytek Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cytek Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytek Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. Cytek Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 555 people.Things to note about Cytek Biosciences performance evaluation
Checking the ongoing alerts about Cytek Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytek Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytek Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 105.23 M. | |
| About 64.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cytek Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytek Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cytek Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytek Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytek Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytek Biosciences' stock. These opinions can provide insight into Cytek Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |